Horizon Therapeutics and Johns Hopkins University School of Medicine have entered a multi-year scientific partnership for advancing autoimmunity and inflammation research.

The collaboration will work on identifying new disease targets and developing therapies to treat serious autoimmune and inflammatory conditions.

Initially, it will focus on the emerging immunometabolism field, and additional projects are set to follow.

Horizon Therapeutics research and development executive vice-president Elizabeth Thompson said: “Collaboration is essential to move science forward, and we are very pleased to begin working with Johns Hopkins University.

“By combining Johns Hopkins capabilities in pre-clinical research with Horizon’s expertise in autoimmunity, our teams will advance translational and research efforts to address the unique needs of different patient populations.”

The research scientists at the company and experts at Johns Hopkins University School of Medicine aim to identify new metabolic pathways.

These pathways lead to autoimmunity and chronic inflammation in different subsets of patients with myositis.

Later, this pathway knowledge will be leveraged to identify new drug targets which may be appropriate for discovering new medicines.

Horizon research vice-president Robert Stoffel said: “As Horizon deepens our footprint in the Maryland area, we believe this collaboration will bolster the world-class scientific thinking and technical capabilities that are found in the Maryland life sciences ecosystem.

“Working hand-in-hand with experts at Johns Hopkins University will allow our teams to better understand the biology of diseases we are investigating and identify new pre-clinical targets that could lead to novel therapeutics.”

The company is focused on discovering, developing, and commercialising medicines which address the critical needs of individuals suffering from rare, autoimmune, and severe inflammatory diseases.

In August, Q32 Bio and Horizon entered a partnership and option agreement to develop ADX-914 for treating autoimmune ailments.